# Boston Scientific

Source: https://nuclide.cc/companies/boston-scientific/  
Nuclide record `boston-scientific` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.

## Summary

Boston Scientific, based in Marlborough, Massachusetts, and listed as BSX, is the medical device company whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer. TheraSphere has held FDA approval for hepatocellular carcinoma since 2021, was studied in the EPOCH trial in colorectal liver metastases, which was positive for progression-free survival, and is being tested in combination with immunotherapy, and the company also sells drug-eluting embolic beads and other interventional oncology devices. Nuclide links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation and transarterial chemoembolisation technology records. Whether device-based liver-directed therapy keeps its role as systemic options improve is the open question. The technology pages carry the trial detail.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Marlborough, MA
- Type: devices
- Website: https://www.bostonscientific.com
- Ticker: BSX

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Boston_Scientific
- Official website: https://www.bostonscientific.com

## Connected records

- isotopes: [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/)
- technologies: [Radioembolisation (TARE / SIRT, yttrium-90)](https://nuclide.cc/technologies/radioembolisation-tare/)
- trials: [TheraSphere With Durvalumab and Tremelimumab for HCC](https://nuclide.cc/trials/nct05063565/)
- drugs: [Yttrium-90 glass microspheres](https://nuclide.cc/drugs/y-90-glass-microspheres/)
- companies: [BWXT Medical](https://nuclide.cc/companies/bwxt-medical/), [Quirem Medical](https://nuclide.cc/companies/quirem-medical/)
- fronts: [Radioembolisation](https://nuclide.cc/fronts/f-radioembolisation/)
- pairings: [Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma](https://nuclide.cc/pairings/tare-plus-durvalumab-hcc/)

---
JSON: https://nuclide.cc/api/v1/entities/boston-scientific.json